Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAP4343 in Treatment-Resistant Major Depressive Episode
NCT03870776Phase 2Completed
- Sponsor
- Mapreg
- Start
- Jun 2019
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MAP4343 in major depressive disorder (MDD) (3 arms), sponsored by Mapreg. Primary endpoint: Hamilton Depression Rating Scale at 43 days. Started Jun 2019; status: completed.
02
Drugs
MAP4343
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03870776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870776.